SUTRO BIOPHARMA, INC. Balance Sheet
STRO|8 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 8 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$174M
FY2025
Cash
$58M
Cash and equivalents
Total Debt
N/A
FY2025
Shareholder Equity
$45M
FY2025
SUTRO BIOPHARMA, INC. had $174M in total assets and $45M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58.1M | $190.3M | $47.3M | $30.4M | $206.2M | $5.0M | $125.3M | $22.0M |
| Accounts Receivable | $4.0M | $8.6M | $36.1M | $7.1M | $12.5M | $5.6M | $6.3M | $2.5M |
| Current Assets | $150.9M | $343.3M | $421.5M | $353.2M | $218.5M | $378.2M | $128.6M | $209.9M |
| PP&E (Net) | $10.6M | $18.2M | $21.9M | $24.6M | $22.6M | $12.9M | $9.6M | $10.9M |
| Total Assets | $173.8M | $387.2M | $470.7M | $406.9M | $341.4M | $394.1M | $156.4M | $223.1M |
| Current Liabilities | $75.1M | $131.9M | $93.7M | $66.5M | $41.7M | $29.6M | $33.0M | $36.4M |
| Total Debt | - | - | - | $16.3M | $25.1M | $24.5M | $8.9M | $10.0M |
| Shareholders' Equity | $44.6M | $149.6M | $252.6M | $332.0M | $97.8M | $131.5M | -$109.0M | -$90.9M |